AnaptysBio, Inc. (ANAB) vs Urogen Pharma (URGN)
- AnaptysBio, Inc. ANAB 45.61 −0.26%
- Urogen Pharma URGN 29.88 +6.33%
AnaptysBio, Inc. and Urogen Pharma are both Biotechnology companies. AnaptysBio, Inc. and Urogen Pharma are of similar size ($1.5B and $1.4B). Urogen Pharma has negative trailing earnings, so its P/E is not meaningful; AnaptysBio, Inc. trades at 73.6×. Urogen Pharma grew revenue faster over the last twelve months: 159.3% against 95.2%. AnaptysBio, Inc. has the higher net margin (6.54% vs −26.3%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, AnaptysBio, Inc. leads on 12 and Urogen Pharma on 4.
Valuation
Profitability
| Metric | ANAB | URGN | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 91.41% | 70.18% |
| Operating margin | 36.14% | (12.36%) | 0.00% |
| Net margin | 6.54% | (26.27%) | 0.00% |
| Free cash flow margin | 0.00% | (52.77%) | 0.00% |
| Return on equity | (365.73%) | 54.65% | (50.72%) |
| Return on assets | 4.76% | (28.78%) | (45.56%) |
| Return on invested capital | 0.00% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack